Trade CRISPR Therapeutics AG - CRSP CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.23 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 40.28 |
| Open | 39.65 |
| 1-Year Change | -40.62% |
| Day's Range | 39.47 - 40.84 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 40.66 | 0.70 | 1.75% | 39.96 | 40.93 | 39.25 |
| Dec 19, 2024 | 40.28 | -1.14 | -2.75% | 41.42 | 41.53 | 39.75 |
| Dec 18, 2024 | 41.00 | -3.27 | -7.39% | 44.27 | 44.61 | 40.55 |
| Dec 17, 2024 | 44.54 | 0.78 | 1.78% | 43.76 | 44.86 | 42.19 |
| Dec 16, 2024 | 44.13 | 0.35 | 0.80% | 43.78 | 45.09 | 43.67 |
| Dec 13, 2024 | 43.73 | -1.22 | -2.71% | 44.95 | 45.16 | 42.76 |
| Dec 12, 2024 | 45.33 | -2.03 | -4.29% | 47.36 | 47.56 | 45.32 |
| Dec 11, 2024 | 47.61 | -1.25 | -2.56% | 48.86 | 49.25 | 47.31 |
| Dec 10, 2024 | 48.60 | -1.13 | -2.27% | 49.73 | 50.33 | 48.25 |
| Dec 9, 2024 | 49.78 | -2.97 | -5.63% | 52.75 | 53.75 | 48.52 |
| Dec 6, 2024 | 52.06 | 2.32 | 4.66% | 49.74 | 52.33 | 49.59 |
| Dec 5, 2024 | 49.45 | -1.50 | -2.94% | 50.95 | 51.02 | 48.96 |
| Dec 4, 2024 | 51.07 | -0.19 | -0.37% | 51.26 | 52.23 | 49.16 |
| Dec 3, 2024 | 51.15 | -2.92 | -5.40% | 54.07 | 54.26 | 51.12 |
| Dec 2, 2024 | 54.86 | 3.91 | 7.67% | 50.95 | 55.41 | 50.59 |
| Nov 29, 2024 | 50.98 | 0.16 | 0.31% | 50.82 | 51.55 | 50.16 |
| Nov 27, 2024 | 50.61 | 1.01 | 2.04% | 49.60 | 50.90 | 49.50 |
| Nov 26, 2024 | 49.24 | -0.52 | -1.05% | 49.76 | 50.29 | 48.34 |
| Nov 25, 2024 | 50.23 | 1.18 | 2.41% | 49.05 | 51.66 | 48.83 |
| Nov 22, 2024 | 47.66 | 1.70 | 3.70% | 45.96 | 47.93 | 45.57 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
CRISPR Therapeutics AG Company profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a revolutionary gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company''s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient''s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, the company engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, duchenne muscular dystrophy, cystic fibrosis, and hurler syndrome. It partners with biopharma companies, academic centers, universities, and other organizations. The company has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to develop and commercialize products for the treatment of Duchenne M. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.| Industry: | Biotechnology & Medical Research (NEC) |
Baarerstrasse 14
ZUG
ZUG 6300
CH
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com